论文部分内容阅读
根据细胞因子之间协同作用的特点，采用重组 Ｄ Ｎ Ａ 技术设计并构建了人 Ｉ Ｌ２ 与 Ｉ Ｆ Ｎα融合基因，并用肝癌组织特异的 Ａ Ｆ Ｐ增强子／ Ａ Ｌ Ｂ启动子调控融合基因在肝癌细胞中的靶向表达．实验结果表明，克隆的 Ｅ Ａ Ｆ Ｐ Ｐ Ａ Ｌ Ｂ联合转录调控序列能调控细胞因子基因在 Ａ Ｆ Ｐ阳性人肝癌细胞中靶向表达， Ｉ Ｌ２／ Ｉ Ｆ Ｎα２ｂ 融合基因的表达水平与感染肝癌细胞的 Ａ Ｆ Ｐ表达水平呈正相关性．实验证明表达的融合蛋白具有 Ｉ Ｌ２ 和 Ｉ Ｆ Ｎ 两种生物学活性的细胞因子．这可能为肝癌基因治疗开辟新途径．
Based on the synergistic characteristics between cytokines, recombinant human N L 2 and I F Nα fusion genes were designed and constructed using recombinant D N A technology, and fusions were regulated by the A F P enhancer/A L B promoter specific for hepatocellular carcinoma. Targeted expression of genes in hepatoma cells. The experimental results show that the cloned E A F P P A L B combined transcriptional regulatory sequences can regulate the expression of cytokine genes in A F P positive human hepatoma cells, and the expression level of I L2/I F Nα2b fusion genes There was a positive correlation between A F P expression level and infection of hepatoma cells. Experiments have shown that the expressed fusion protein has two biologically active cytokines, I L 2 and I F N . This may open up new ways for gene therapy of liver cancer.